Univariate analysis of transplant outcomes by disease and donor/recipient CMV serology
| Disease . | D+/R+ [% (95% CI)] . | D+/R− [% (95% CI)] . | D−/R+ [% (95% CI)] . | D−/R− [% (95% CI)] . | P value . |
|---|---|---|---|---|---|
| Relapse at 3 years | |||||
| AML | 39 (37- 41)% | 34 (31-38)% | 39 (37-42)% | 37 (34-39)% | .13 |
| ALL | 37 (34-41)% | 27 (21-32)% | 29 (25-33)% | 33 (29-37)% | .003 |
| CML | 33 (28-38)% | 30 (21-39)% | 34 (27-41)% | 28 (23-33)% | .44 |
| MDS | 26 (22-31)% | 38 (29-46)% | 34 (29-39)% | 30 (26-35)% | .06 |
| NRM at 3 years | |||||
| AML | 18 (16-20)% | 21 (18-24)% | 20 (18-22)% | 15 (13-17)% | <.001 |
| ALL | 25 (22-29)% | 18 (14-23)% | 22 (18-26)% | 16 (13-19)% | <.001 |
| CML | 17 (14-21)% | 15 (9-22)% | 15 (11-21)% | 14 (10-18)% | .64 |
| MDS | 28 (23-33)% | 23 (16-31)% | 23 (19-28)% | 23 (19-27)% | .49 |
| OS at 3 years | |||||
| AML | 47 (45-49)% | 51 (46-55)% | 45 (43-48)% | 54 (51-56)% | <.001 |
| ALL | 44 (40-48)% | 59 (53-65)% | 54 (50-59)% | 60 (56-64)% | <.001 |
| CML | 61 (56-66)% | 66 (57-74)% | 61 (55-68)% | 70 (64-75)% | .08 |
| MDS | 48 (43-54)% | 46 (37-55)% | 47 (41-52)% | 51 (45-56)% | .74 |
| Disease-free survival at 3 years | |||||
| AML | 43 (41-45)% | 45 (41-49)% | 41 (38-43)% | 49 (46-52)% | <.001 |
| ALL | 37 (34-41)% | 55 (49-61)% | 49 (45-54)% | 52 (47-56)% | <.001 |
| CML | 50 (45-55)% | 56 (46-65)% | 51 (44-58)% | 58 (53-64)% | .13 |
| MDS | 46 (41-51%) | 39 (30-48)% | 43 (37-48) | 47 (42-52)% | .036 |
| aGVHD at 1 year | |||||
| AML | 34(32-37)% | 35 (31-39)% | 37 (35-39)% | 38 (36-41)% | .11 |
| ALL | 37 (33-41)% | 42 (35-48)% | 39 (35-44)% | 34 (30-38)% | .16 |
| CML | 35 (30-39)% | 43 (34-52)% | 48 (41-55)% | 45 (39-50)% | .004 |
| MDS | 41 (36-46)% | 46 (37-55)% | 42 (37-48)% | 45(40-50)% | .66 |
| cGVHD at 3 years | |||||
| AML | 44 (42-46)% | 50 (46-54)% | 47 (44-49)% | 51 (48-54)% | <.001 |
| ALL | 46 (42-50)% | 51 (45-57)% | 46 (41-50)% | 43 (38-47)% | .18 |
| CML | 51 (46-56)% | 49 (39-58)% | 56 (48-62)% | 44 (49-60)% | .57 |
| MDS | 48 (43-54)% | 49 (40-58)% | 50 (45-56)% | 52 (47-57)% | .76 |
| Disease . | D+/R+ [% (95% CI)] . | D+/R− [% (95% CI)] . | D−/R+ [% (95% CI)] . | D−/R− [% (95% CI)] . | P value . |
|---|---|---|---|---|---|
| Relapse at 3 years | |||||
| AML | 39 (37- 41)% | 34 (31-38)% | 39 (37-42)% | 37 (34-39)% | .13 |
| ALL | 37 (34-41)% | 27 (21-32)% | 29 (25-33)% | 33 (29-37)% | .003 |
| CML | 33 (28-38)% | 30 (21-39)% | 34 (27-41)% | 28 (23-33)% | .44 |
| MDS | 26 (22-31)% | 38 (29-46)% | 34 (29-39)% | 30 (26-35)% | .06 |
| NRM at 3 years | |||||
| AML | 18 (16-20)% | 21 (18-24)% | 20 (18-22)% | 15 (13-17)% | <.001 |
| ALL | 25 (22-29)% | 18 (14-23)% | 22 (18-26)% | 16 (13-19)% | <.001 |
| CML | 17 (14-21)% | 15 (9-22)% | 15 (11-21)% | 14 (10-18)% | .64 |
| MDS | 28 (23-33)% | 23 (16-31)% | 23 (19-28)% | 23 (19-27)% | .49 |
| OS at 3 years | |||||
| AML | 47 (45-49)% | 51 (46-55)% | 45 (43-48)% | 54 (51-56)% | <.001 |
| ALL | 44 (40-48)% | 59 (53-65)% | 54 (50-59)% | 60 (56-64)% | <.001 |
| CML | 61 (56-66)% | 66 (57-74)% | 61 (55-68)% | 70 (64-75)% | .08 |
| MDS | 48 (43-54)% | 46 (37-55)% | 47 (41-52)% | 51 (45-56)% | .74 |
| Disease-free survival at 3 years | |||||
| AML | 43 (41-45)% | 45 (41-49)% | 41 (38-43)% | 49 (46-52)% | <.001 |
| ALL | 37 (34-41)% | 55 (49-61)% | 49 (45-54)% | 52 (47-56)% | <.001 |
| CML | 50 (45-55)% | 56 (46-65)% | 51 (44-58)% | 58 (53-64)% | .13 |
| MDS | 46 (41-51%) | 39 (30-48)% | 43 (37-48) | 47 (42-52)% | .036 |
| aGVHD at 1 year | |||||
| AML | 34(32-37)% | 35 (31-39)% | 37 (35-39)% | 38 (36-41)% | .11 |
| ALL | 37 (33-41)% | 42 (35-48)% | 39 (35-44)% | 34 (30-38)% | .16 |
| CML | 35 (30-39)% | 43 (34-52)% | 48 (41-55)% | 45 (39-50)% | .004 |
| MDS | 41 (36-46)% | 46 (37-55)% | 42 (37-48)% | 45(40-50)% | .66 |
| cGVHD at 3 years | |||||
| AML | 44 (42-46)% | 50 (46-54)% | 47 (44-49)% | 51 (48-54)% | <.001 |
| ALL | 46 (42-50)% | 51 (45-57)% | 46 (41-50)% | 43 (38-47)% | .18 |
| CML | 51 (46-56)% | 49 (39-58)% | 56 (48-62)% | 44 (49-60)% | .57 |
| MDS | 48 (43-54)% | 49 (40-58)% | 50 (45-56)% | 52 (47-57)% | .76 |
P values with statistical significance (P < .05) are noted in bold type.